Alteration of L-Dopa decarboxylase expression in SARS-CoV-2 infection and its association with the interferon-inducible ACE2 isoform.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2021
Historique:
received: 01 12 2020
accepted: 06 06 2021
entrez: 29 6 2021
pubmed: 30 6 2021
medline: 13 7 2021
Statut: epublish

Résumé

L-Dopa decarboxylase (DDC) is the most significantly co-expressed gene with ACE2, which encodes for the SARS-CoV-2 receptor angiotensin-converting enzyme 2 and the interferon-inducible truncated isoform dACE2. Our group previously showed the importance of DDC in viral infections. We hereby aimed to investigate DDC expression in COVID-19 patients and cultured SARS-CoV-2-infected cells, also in association with ACE2 and dACE2. We concurrently evaluated the expression of the viral infection- and interferon-stimulated gene ISG56 and the immune-modulatory, hypoxia-regulated gene EPO. Viral load and mRNA levels of DDC, ACE2, dACE2, ISG56 and EPO were quantified by RT-qPCR in nasopharyngeal swab samples from COVID-19 patients, showing no or mild symptoms, and from non-infected individuals. Samples from influenza-infected patients were analyzed in comparison. SARS-CoV-2-mediated effects in host gene expression were validated in cultured virus-permissive epithelial cells. We found substantially higher gene expression of DDC in COVID-19 patients (7.6-fold; p = 1.2e-13) but not in influenza-infected ones, compared to non-infected subjects. dACE2 was more elevated (2.9-fold; p = 1.02e-16) than ACE2 (1.7-fold; p = 0.0005) in SARS-CoV-2-infected individuals. ISG56 (2.5-fold; p = 3.01e-6) and EPO (2.6-fold; p = 2.1e-13) were also increased. Detected differences were not attributed to enrichment of specific cell populations in nasopharyngeal tissue. While SARS-CoV-2 virus load was positively associated with ACE2 expression (r≥0.8, p<0.001), it negatively correlated with DDC, dACE2 (r≤-0.7, p<0.001) and EPO (r≤-0.5, p<0.05). Moreover, a statistically significant correlation between DDC and dACE2 expression was observed in nasopharyngeal swab and whole blood samples of both COVID-19 and non-infected individuals (r≥0.7). In VeroE6 cells, SARS-CoV-2 negatively affected DDC, ACE2, dACE2 and EPO mRNA levels, and induced cell death, while ISG56 was enhanced at early hours post-infection. Thus, the regulation of DDC, dACE2 and EPO expression in the SARS-CoV-2-infected nasopharyngeal tissue is possibly related with an orchestrated antiviral response of the infected host as the virus suppresses these genes to favor its propagation.

Identifiants

pubmed: 34185793
doi: 10.1371/journal.pone.0253458
pii: PONE-D-20-37782
pmc: PMC8241096
doi:

Substances chimiques

Adaptor Proteins, Signal Transducing 0
EPO protein, human 0
IFIT1 protein, human 0
Protein Isoforms 0
RNA-Binding Proteins 0
Erythropoietin 11096-26-7
ACE2 protein, human EC 3.4.17.23
Angiotensin-Converting Enzyme 2 EC 3.4.17.23
Dopa Decarboxylase EC 4.1.1.-
Aromatic-L-Amino-Acid Decarboxylases EC 4.1.1.28
DDC protein, human EC 4.1.1.28

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0253458

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Eur Rev Med Pharmacol Sci. 2016 Dec;20(24):5067-5076
pubmed: 28051265
Apoptosis. 2021 Feb;26(1-2):7-8
pubmed: 33512610
J Virol. 2005 Dec;79(23):14614-21
pubmed: 16282461
J Med Virol. 2020 Oct;92(10):1743-1744
pubmed: 32246784
Clin Sci (Lond). 2014 Apr;126(7):507-16
pubmed: 24147777
PLoS Pathog. 2011 Oct;7(10):e1002289
pubmed: 22022264
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Signal Transduct Target Ther. 2020 Oct 9;5(1):235
pubmed: 33037188
Gene. 2019 Nov 30;719:144075
pubmed: 31449843
Int J Lab Hematol. 2021 Jul;43 Suppl 1:142-151
pubmed: 33554466
Cell Rep. 2021 Apr 20;35(3):109020
pubmed: 33852916
J Virol. 2000 Jun;74(11):4957-66
pubmed: 10799569
Cell Death Differ. 2004 Jul;11 Suppl 1:S37-44
pubmed: 15243580
Cells. 2018 Dec 01;7(12):
pubmed: 30513781
Front Cardiovasc Med. 2017 Jul 20;4:48
pubmed: 28775986
J Immunol Res. 2016;2016:3160486
pubmed: 27795960
PLoS One. 2010 Jun 17;5(6):e11159
pubmed: 20567522
Cell Host Microbe. 2021 Feb 10;29(2):267-280.e5
pubmed: 33357464
Emerg Microbes Infect. 2020 Dec;9(1):1418-1428
pubmed: 32529952
Virus Res. 2021 Apr 2;295:198283
pubmed: 33418027
Nat Rev Immunol. 2020 Jul;20(7):397-398
pubmed: 32457522
BMC Cancer. 2006 Jan 27;6:26
pubmed: 16438736
J Clin Invest. 1991 Sep;88(3):789-97
pubmed: 1653276
Microb Pathog. 2021 Sep;158:105114
pubmed: 34333072
J Gen Virol. 1979 Apr;43(1):247-52
pubmed: 113494
Microbes Infect. 2012 Mar;14(3):238-46
pubmed: 22094132
Biomolecules. 2020 Apr 12;10(4):
pubmed: 32290638
Biochimie. 2020 Oct;177:78-86
pubmed: 32835737
J Neurosci Nurs. 2000 Aug;32(4):234-8
pubmed: 10994538
Mol Med. 2020 Jun 16;26(1):58
pubmed: 32546125
Cells. 2019 Aug 05;8(8):
pubmed: 31387309
Biochimie. 2019 May;160:76-87
pubmed: 30796964
Zhonghua Er Bi Yan Hou Ke Za Zhi. 2002 Feb;37(1):34-7
pubmed: 12768792
Pharmaceuticals (Basel). 2021 Jan 12;14(1):
pubmed: 33445640
J Infect. 2020 Jun;80(6):607-613
pubmed: 32283152
Bioorg Med Chem. 2011 May 15;19(10):3120-7
pubmed: 21524588
J Cell Physiol. 2019 Nov;234(11):20420-20431
pubmed: 30989646
Nat Genet. 2020 Dec;52(12):1283-1293
pubmed: 33077916
J Inflamm (Lond). 2020 Oct 29;17:33
pubmed: 33139969
J Virol. 2015 Sep;89(17):8701-12
pubmed: 26109733
Am J Respir Cell Mol Biol. 2005 May;32(5):395-403
pubmed: 15695738
Biomed Res Int. 2017;2017:7404912
pubmed: 28127559
J Virol. 2013 Mar;87(5):2935-48
pubmed: 23269812
Front Cell Neurosci. 2018 Nov 26;12:461
pubmed: 30534058
Nat Biotechnol. 2020 Aug;38(8):970-979
pubmed: 32591762
Cell. 2020 May 28;181(5):1036-1045.e9
pubmed: 32416070
Emerg Microbes Infect. 2021 Dec;10(1):1065-1076
pubmed: 34013835
Nat Genet. 2021 Feb;53(2):205-214
pubmed: 33432184
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Am J Physiol Lung Cell Mol Physiol. 2009 Oct;297(4):L631-40
pubmed: 19592460
J Biol Chem. 2004 Apr 9;279(15):14871-8
pubmed: 14744852
J Med Virol. 2020 Oct;92(10):1793-1794
pubmed: 32311107
Nature. 2020 Jul;583(7816):459-468
pubmed: 32353859
Nat Med. 2020 May;26(5):681-687
pubmed: 32327758
J Neurol Sci. 1975 Sep;26(1):49-60
pubmed: 1159458
J Neurochem. 2009 Jul;110(2):622-30
pubmed: 19457096

Auteurs

George Mpekoulis (G)

Laboratory of Molecular Virology, Hellenic Pasteur Institute, Athens, Greece.

Efseveia Frakolaki (E)

Laboratory of Molecular Virology, Hellenic Pasteur Institute, Athens, Greece.

Styliani Taka (S)

Allergy and Clinical Immunology Unit, 2nd Pediatric Clinic, National and Kapodistrian University of Athens, Athens, Greece.

Anastasios Ioannidis (A)

Department of Nursing, University of Peloponnese, Sparti, Greece.

Alice G Vassiliou (AG)

First Department of Critical Care Medicine & Pulmonary Services, GP Livanos and M Simou Laboratories, National and Kapodistrian University of Athens Medical School, Evangelismos Hospital, Athens, Greece.

Katerina I Kalliampakou (KI)

Laboratory of Molecular Virology, Hellenic Pasteur Institute, Athens, Greece.

Kostas Patas (K)

Department of Medical Biopathology, Medical School, University of Athens, Eginition Hospital, Athens, Greece.

Ioannis Karakasiliotis (I)

Laboratory of Biology, Department of Medicine, Democritus University of Thrace, Alexandroupolis, Greece.

Vassilis Aidinis (V)

Institute for Bioinnovation, Biomedical Sciences Research Center "Alexander Fleming", Athens, Greece.

Stylianos Chatzipanagiotou (S)

Department of Medical Biopathology, Medical School, University of Athens, Eginition Hospital, Athens, Greece.

Emmanouil Angelakis (E)

Department of Diagnostics, Hellenic Pasteur Institute, Athens, Greece.
Aix Marseille Univ, IRD, IHU Méditerranée Infection, VITROME, Marseille, France.

Dido Vassilacopoulou (D)

Section of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens, Athens, Greece.

Niki Vassilaki (N)

Laboratory of Molecular Virology, Hellenic Pasteur Institute, Athens, Greece.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH